Enrico Cagliero is an Endocrinology/Metabolic physician affiliated with Harvard University. OpenAlex indexes 132 publications with 11,432 citations (h-index 50); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
50 Staniford St
3rd Floor S50 3 Diabetes Unit
Boston, MA 021142517
Telephone
617-726-8722Registry record last updated 25 Jul 2012.
Clinical trials
- Efficacy of Structured Insulin Order
Sponsor: Massachusetts General Hospital
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
96%GLP-1 receptor agonist58.2%Mounjaro41%Ozempic34%Trulicity20%Rybelsus5%Part D<11 patientsInsulin Analog20.4%Lantus Solostar28%Basaglar Kwikpen U-10022%Tresiba Flextouch U-10016%Humalog14%Lantus11%Humalog Kwikpen U-1009%Part D<11 patients+ 3 more classes in this area
Hormonal (systemic)
2.1%l-Thyroxine2.1%Levothyroxine Sodium100%Part D<11 patientsCardiovascular
1.9%Beta blocker1.9%Metoprolol Succinate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2004–2008 per NIH RePORTER. The latest:
- EXENATIDE AS ADJUVANT THERAPY IN ISLET CELL TRANSPLANTATION
Massachusetts General Hospital
FY2008$7,285M01RR001066 - DIABETIC PTS RECIPIENTS OF RENAL ALLOGRAFTS USING THE EDMONTON PROTOCOL IMMUNO
Massachusetts General Hospital
FY2007$643M01RR001066 - ISLET TRANS T1 DIABETIC PTS USING EDMONTON PROTOCOL STEROID FREE IMMUONO
Massachusetts General Hospital
FY2007$321M01RR001066
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Benjamin Ebert, MD
Harvard University
Mark Shrime, MD
Harvard University
Thoralf Sundt, MD
Harvard University
Dhaval Kolte, MBBS, PhD
Harvard University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”